Companion Diagnostics

Reliance Life Sciences is focusing on the contemporary field of Theranostics, with equivalent emphasis on diagnostics and therapy. Thus, selection of patients for optimal treatment with targeted therapy such as monoclonal antibodies or small molecules (like tyrosine kinase inhibitors) require molecular diagnostics to detect mutations in metastatic colorectal cancers, non-small cell lung cancers, gastrointestinal stromal tumor, or MGMT methylation to select patients for treatment with Temozolomide, BCR-ABL kinase domain mutations for predicting response to drug regimen.

Companion Diagnostic Services

• EGFR Hotspot Mutations
• Alk gene rearrangement by FISH
• KRAS Mutation Analysis
• BRAF Mutation Analysis
• NRAS Mutation Analysis
• BCR/ABL transcript ratio monitoring
• CD20 biomarker
• MGMT MS PCR
• HER-2/neu
• ER/ PgR biomarker
• c-KIT and PDGFRA mutation Analysis